Drug Approval | September 21, 2022
Tezspire approved in the EU for the treatment of severe asthma
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
Successfully removed peanut from the child’s left lung through bronchoscopy
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
The drug is indicated for use in combination with other drugs
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
The three prequalified products are manufactured by the originator company, Roche, but the listings should pave the way for more companies coming forward to seek WHO prequalification
Laglo Soft lotion comes with a unique technology that enhances moisturisation and restructures the skin
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
